Amy Schacterle - Nov 5, 2024 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
Chief Regulatory Officer
Signature
/s/ Derek Meisner, Attorney-in-Fact
Stock symbol
ABOS
Transactions as of
Nov 5, 2024
Transactions value $
$0
Form type
4
Date filed
11/6/2024, 05:27 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABOS Employee Stock Option (right to buy) Award $0 +340K $0.00 340K Nov 5, 2024 Common Stock 340K $2.95 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on November 5, 2025, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest and become exercisable each month thereafter, subject to Reporting Person continuing to provide service through each such date.